桂林八加一药物研究

Ba Jia Yi Pharmaceutical (formerly known as Guilin Eight Plus One Pharmaceutical) is an innovative Chinese biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for major chronic diseases, particularly in the cardiovascular, cerebrovascular, and inflammatory fields. The company's pipeline features three Class 1 new drugs: Marifutide (注射用吗利福肽), a neuroprotective peptide in Phase II clinical trials for acute ischemic stroke; Compound Shenxiong Dripping Pills (复方参芎滴丸 / BJY-802), a Class 1 traditional Chinese medicine in Phase IIb trials for coronary heart disease; and Flavonol Glycoside Tablets (黄酮醇糖苷片 / BJY-803), a Class 1 chemical drug that has completed Phase I trials for hypercholesterolemia. In August 2026, Tonghua Golden Horse (通化金马) announced an intent to acquire a controlling stake in Ba Jia Yi Pharmaceutical to expand its pipeline in the neurology and chronic disease sectors.